KR900004352A - 뇌졸중 치료용 의약 - Google Patents

뇌졸중 치료용 의약 Download PDF

Info

Publication number
KR900004352A
KR900004352A KR1019890013434A KR890013434A KR900004352A KR 900004352 A KR900004352 A KR 900004352A KR 1019890013434 A KR1019890013434 A KR 1019890013434A KR 890013434 A KR890013434 A KR 890013434A KR 900004352 A KR900004352 A KR 900004352A
Authority
KR
South Korea
Prior art keywords
active compound
use according
nmol
stroke
binding
Prior art date
Application number
KR1019890013434A
Other languages
English (en)
Other versions
KR0135307B1 (ko
Inventor
트라버 외르크
빌렌베르크 게르하르트-빌헬름
Original Assignee
하인리히 스페크트메이어 외르크 트라버
트로폰 베르케 게엠베하 운트 캄파니 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하인리히 스페크트메이어 외르크 트라버, 트로폰 베르케 게엠베하 운트 캄파니 카게 filed Critical 하인리히 스페크트메이어 외르크 트라버
Publication of KR900004352A publication Critical patent/KR900004352A/ko
Priority to KR1019970061359A priority Critical patent/KR0149275B1/ko
Priority to KR1019970061361A priority patent/KR0149274B1/ko
Application granted granted Critical
Publication of KR0135307B1 publication Critical patent/KR0135307B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Instructional Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

뇌졸중 치료용 의약
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 세로토닌 길항제로 작용하며 5HT1A수용체에 결합시의 결합 강도가 10,000nmol/1 미만인 유효 화합물의 뇌졸증 치료용 의약의 제조 용도.
  2. 제1항에 있어서, 유효 화합물의 결합 강도가 1,000nmol/1 미만임을 특징으로 하는 화합물의 용도.
  3. 제1항 또는 제2항에 있어서, 유효 화합물의 결합 강도가 0.1 내지 100nmol/1임을 특징으로 하는 화합물의 용도.
  4. 제1항 내지 제3항 중 어느 하나의 항에 있어서, 유효화합물을 아릴-및 헤타릴-피페라진류로부터 선택하여 사용함을 특징으로 하는 용도.
  5. 제1항 내지 제3항 중 어느 하나의 항에 있어서, 유효화합물을 아미노테트라히드로벤즈인돌류로부터 선택하여 사용함을 특징으로 하는 용도.
  6. 제1항 내지 제3항 중 어느 하나의 항에 있어서, 유효화합물을 인돌라민류로부터 선택하여 사용함을 특징으로 하는 용도.
  7. 제1항 내지 제3항 중 어느 하나의 항에 있어서, 유효화합물을 아미노알킬-벤조디옥산류로부터 선택하여 사용함을 특징으로 하는 용도.
  8. 제1항 내지 제3항 중 어느 하나의 항에 있어서, 유효화합물을 아미노테트랄린류로부터 선택하여 사용함을 특징으로 하는 용도.
  9. 제1항 내지 제3항 중 어느 하나의 항에 있어서, 유효화합물을 아미노크로만류 및 아미노티오피란류로부터 선택하여 사용함을 특징으로 하는 용도.
  10. 제1항 내지 제3항 중 어느 하나의 항에 있어서, 유효화합물을 인돌릴-알킬피페리딘류로부터 선택하여 사용함을 특징으로 하는 용도.
  11. 제1항 내지 제3항 중 어느 하나의 항에 있어서, 유효화합물을 테트라히드로피리딘류로부터 선택하여 사용함을 특징으로 하는 용도.
  12. 세로토닌 길항제로서 작용하고 5HT1A수용체에 결합시의 결합 강도가 10,000nmol/1 미만인 유효 화합물을 함유한 뇌졸중 치료용 의약.
  13. 제12항에 있어서, 유효 화합물을 0.01 내지 20중량% 함유한 의약.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890013434A 1988-09-20 1989-09-19 뇌졸중 치료용 의약 KR0135307B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1019970061359A KR0149275B1 (en) 1988-09-20 1997-11-20 Medicaments for the treatment of cerebral apoplexy
KR1019970061361A KR0149274B1 (en) 1988-09-20 1997-11-20 Medicaments for the treatment of cerebral apoplexy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3831888A DE3831888A1 (de) 1988-09-20 1988-09-20 Arzneimittel zur behandlung von apoplexia cerebri
DEP3831888.1 1988-09-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019970061360A Division KR0146486B1 (ko) 1988-09-20 1997-11-20 뇌졸증 치료용 의약

Publications (2)

Publication Number Publication Date
KR900004352A true KR900004352A (ko) 1990-04-12
KR0135307B1 KR0135307B1 (ko) 1998-04-23

Family

ID=6363313

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019890013434A KR0135307B1 (ko) 1988-09-20 1989-09-19 뇌졸중 치료용 의약
KR1019970061360A KR0146486B1 (ko) 1988-09-20 1997-11-20 뇌졸증 치료용 의약

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019970061360A KR0146486B1 (ko) 1988-09-20 1997-11-20 뇌졸증 치료용 의약

Country Status (15)

Country Link
US (3) US4988700A (ko)
EP (1) EP0360077B1 (ko)
JP (1) JP2669507B2 (ko)
KR (2) KR0135307B1 (ko)
AT (1) ATE91623T1 (ko)
AU (1) AU619895B2 (ko)
CA (1) CA1331139C (ko)
DE (2) DE3831888A1 (ko)
DK (1) DK175128B1 (ko)
ES (1) ES2058426T3 (ko)
FI (1) FI894404A (ko)
HU (1) HU203475B (ko)
IE (1) IE62697B1 (ko)
IL (1) IL91660A (ko)
PH (1) PH26920A (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2097607A1 (en) * 1990-12-24 1992-06-24 Marcel Hibert Use of certain glutarimide derivatives in the treatment of depression and mania
DE4135473A1 (de) * 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung
ES2085247T1 (es) * 1992-09-25 1996-06-01 Synaptic Pharma Corp Receptores adrenergicos alfa 1 humanos que codifican dna y sus utilizaciones.
AU5446894A (en) * 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
ATE255888T1 (de) 1998-06-01 2003-12-15 Ortho Mcneil Pharm Inc Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000004012A1 (en) 1998-07-17 2000-01-27 Synaptic Pharmaceutical Corporation COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
DE19900544A1 (de) * 1999-01-11 2000-07-13 Basf Ag Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie
US20040106623A1 (en) * 1999-07-16 2004-06-03 Synaptic Pharmaceutical Corporation Compounds specific for the human alpha1d adrenergic receptor and uses thereof
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040077996A1 (en) * 2002-10-22 2004-04-22 Jasperson Keith E. Drug infusion system with multiple medications
BRPI0607517A2 (pt) 2005-04-13 2009-09-08 Neuraxon Inc compostos de indol substituìdo, composição farmacêutica compreendendo o mesmo, método para tratar e uso do mesmo
WO2007118314A1 (en) * 2006-04-13 2007-10-25 Neuraxon, Inc. 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
AU2008323526A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
EP2219449A4 (en) * 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
KR102357405B1 (ko) 2021-05-07 2022-02-09 정진구 호흡기 운동기구

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810748D0 (en) * 1988-05-06 1988-06-08 Beecham Wuelfing Gmbh & Co Kg Novel treatment

Also Published As

Publication number Publication date
KR0146486B1 (ko) 1998-08-17
ES2058426T3 (es) 1994-11-01
DE3831888A1 (de) 1990-03-29
IE62697B1 (en) 1995-02-22
HU203475B (en) 1991-08-28
US5155128A (en) 1992-10-13
EP0360077B1 (de) 1993-07-21
EP0360077A3 (de) 1992-03-11
PH26920A (en) 1992-12-03
CA1331139C (en) 1994-08-02
DK175128B1 (da) 2004-06-07
EP0360077A2 (de) 1990-03-28
IL91660A0 (ko) 1990-04-29
FI894404A0 (fi) 1989-09-18
DE58904960D1 (de) 1993-08-26
US5070102A (en) 1991-12-03
AU619895B2 (en) 1992-02-06
JPH02121935A (ja) 1990-05-09
IL91660A (en) 1993-08-18
DK461689D0 (da) 1989-09-19
HUT52699A (en) 1990-08-28
IE892990L (en) 1990-03-20
AU4145689A (en) 1990-03-29
KR0135307B1 (ko) 1998-04-23
US4988700A (en) 1991-01-29
DK461689A (da) 1990-03-21
JP2669507B2 (ja) 1997-10-29
ATE91623T1 (de) 1993-08-15
FI894404A (fi) 1990-03-21

Similar Documents

Publication Publication Date Title
KR900004352A (ko) 뇌졸중 치료용 의약
DE69226369D1 (de) System mit erhöhender Hautpenetration für verbesserte topische Verabreichung von Arzneimitteln
KR940006587A (ko) 어류 기생충의 구제방법
KR870006891A (ko) 구강 위생 조성물
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
KR890008086A (ko) 사이클로헥산 유도체
KR900005978A (ko) 키니딘, 아르테미시닌 및 이의 유도체를 사용한 항말라리아 조성물 및 치료방법
BR0013012A (pt) Composição contendo substância ativa, sua produção e seu uso
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
KR890000009A (ko) 농업용 생리활성제
KR890001540A (ko) 심부전증 치료제
KR880006330A (ko) 코팅 조성물
EA199800573A1 (ru) Таблетки с высоким содержанием фамцикловира
KR890011527A (ko) 살균성4,5-디클로로-1,2-디티올-3-온 조성물
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR920016104A (ko) 노인성 특발적 백내장 약제 제조를 위한 칼시토닌의 국소적용 용도 및 이의 약제학적 조성물
KR900017599A (ko) 종양 치료용 약학 조성물
KR890011595A (ko) 서맥 및 서부정맥 치료제
KR880000094A (ko) 위염치료제
KR890001556A (ko) 약제학적 조성물
KR890001543A (ko) 당뇨병 치료제
KR920702623A (ko) 진해제
KR890009270A (ko) 식물 보호용 살균제
KR960013368A (ko) 토릴린을 함유하는 항암제 활성 증강용 조성물
KR890007717A (ko) 약제 디스펜서

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070102

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee